1. Home
  2. MMED vs RCUS Comparison

MMED vs RCUS Comparison

Compare MMED & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMED

MiniMed Group Inc. Common Stock

N/A

Current Price

$16.97

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$28.37

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMED
RCUS
Founded
1983
2015
Country
United States
United States
Employees
2800
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.8B
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
MMED
RCUS
Price
$16.97
$28.37
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$22.56
$31.90
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
06-03-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$247,000,000.00
Revenue This Year
$15.99
N/A
Revenue Next Year
$10.00
$45.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.65
$8.84
52 Week High
$17.86
$31.74

Technical Indicators

Market Signals
Indicator
MMED
RCUS
Relative Strength Index (RSI) 67.21 53.36
Support Level $14.70 $19.78
Resistance Level N/A $28.72
Average True Range (ATR) 0.88 1.42
MACD 0.11 -0.41
Stochastic Oscillator 88.11 45.17

Price Performance

Historical Comparison
MMED
RCUS

About MMED MiniMed Group Inc. Common Stock

Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: